Drug Patents owned by Janssen Prods
1. List of Edurant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(8 days from now) | |
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(7 months ago) | |
| US7638522 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(11 days from now) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; In combination wi...
Dosage: TABLET;ORAL
EDURANT family patents
30
United States
19
European Union
16
Norway
13
Hungary
9
Japan
8
Australia
7
Korea, Republic of
7
China
6
Lithuania
6
Croatia
6
Brazil
6
Spain
5
Denmark
5
Hong Kong
5
Slovenia
5
Luxembourg
4
Israel
4
Mexico
4
AP
4
Portugal
4
Poland
4
Taiwan, Province of China
4
EA
4
Canada
4
New Zealand
3
South Africa
3
Austria
3
Belgium
3
Argentina
3
Cyprus
3
Ukraine
2
Costa Rica
2
Malaysia
2
Nicaragua
1
OA
1
Egypt
1
Jordan
1
Germany
1
Singapore
1
Netherlands
1
RS
1
Panama
1
ME
2. List of Olysio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7671032 | JANSSEN PRODS | HCV NS-3 serine protease inhibitors |
May, 2025
(2 years from now) | |
| US8349869 | JANSSEN PRODS | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
| US8754106 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
| US8741926 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
| US9040562 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
| US9856265 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
| US8148399 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9353103 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
| US9623022 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(3 years from now) | |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
Market Authorisation Date: 22 November, 2013
Treatment: Method of treating hepatitis c
Dosage: CAPSULE;ORAL
OLYSIO family patents
15
United States
9
European Union
5
Argentina
5
Sweden
5
China
5
Japan
4
Denmark
4
Hong Kong
4
Spain
4
Korea, Republic of
4
Poland
3
Israel
3
South Africa
3
Austria
3
Australia
3
Slovenia
3
Norway
3
Costa Rica
3
Germany
3
Brazil
3
Croatia
3
Portugal
3
Cyprus
3
Malaysia
3
Taiwan, Province of China
3
RS
3
Ecuador
3
Ukraine
3
EA
3
Canada
3
New Zealand
2
Hungary
2
Nicaragua
2
Luxembourg
2
ME
1
El Salvador
1
Uruguay
1
AP
1
Singapore
1
Honduras
1
Guatemala
1
Netherlands
1
Peru
3. List of Prezcobix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(10 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987
(Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(1 year, 4 months from now) | |
|
US7700645
(Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(4 years from now) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing a...
Dosage: TABLET;ORAL
PREZCOBIX family patents
42
United States
24
European Union
17
Japan
16
Spain
13
Portugal
12
Australia
12
Hungary
12
Korea, Republic of
11
Denmark
11
Slovenia
11
Lithuania
11
Norway
10
Croatia
10
Cyprus
10
China
9
Poland
8
Hong Kong
8
Singapore
8
EA
7
New Zealand
6
Mexico
6
AP
6
Canada
5
Argentina
5
Brazil
5
RS
5
Taiwan, Province of China
5
ME
4
Ukraine
3
Israel
3
South Africa
2
Colombia
2
Ecuador
2
Luxembourg
1
Uruguay
1
Netherlands
1
Peru
1
San Marino
1
Chile
4. List of Prezista drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(10 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987
(Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(1 year, 4 months from now) | |
|
US7700645
(Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(4 years from now) | |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 16 December, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
PREZISTA family patents
8
United States
6
European Union
4
Spain
3
Denmark
3
Slovenia
3
Portugal
3
Cyprus
2
Australia
2
Korea, Republic of
1
South Africa
1
Mexico
1
Hong Kong
1
Lithuania
1
Hungary
1
Norway
1
AP
1
Brazil
1
Croatia
1
Poland
1
China
1
Japan
1
EA
1
Canada
1
New Zealand
5. List of Symtuza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(10 months from now) | |
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
| US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | JANSSEN PRODS | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 1 month ago) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
| US10786518 | JANSSEN PRODS | Compositions and methods of treating HIV |
Jul, 2038
(15 years from now) | |
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...
Dosage: TABLET;ORAL
SYMTUZA family patents
65
United States
31
European Union
27
Japan
19
Spain
18
Australia
16
Norway
16
Portugal
15
Hungary
15
Korea, Republic of
14
Denmark
14
Slovenia
14
Lithuania
14
China
13
Croatia
13
Cyprus
11
Hong Kong
11
Poland
11
Canada
11
New Zealand
10
EA
9
Mexico
9
Singapore
8
AP
8
Brazil
6
Argentina
6
RS
6
Taiwan, Province of China
6
Ukraine
6
ME
5
South Africa
4
Israel
3
Colombia
3
Chile
3
Ecuador
3
Luxembourg
2
Morocco
2
Uruguay
2
Netherlands
2
Peru
2
San Marino
2
Czech Republic
1
OA
1
Turkey
1
Belgium
1
Costa Rica
1
Moldova, Republic of
1
Iceland
1
India
1
Bulgaria
1
Estonia
6. List of Yondelis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(4 years from now) | |
|
US8895557
(Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
Market Authorisation Date: 23 October, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
YONDELIS family patents
3
United States
2
Argentina
2
Peru
2
China
1
Israel
1
South Africa
1
Denmark
1
El Salvador
1
Austria
1
Mexico
1
Australia
1
Jordan
1
Russia
1
Slovenia
1
Hong Kong
1
Uruguay
1
Norway
1
Germany
1
Croatia
1
Brazil
1
Honduras
1
Guatemala
1
Portugal
1
Cyprus
1
Malaysia
1
Spain
1
Korea, Republic of
1
Poland
1
RS
1
United Kingdom
1
Taiwan, Province of China
1
Ukraine
1
Japan
1
Canada
1
Panama
1
New Zealand
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic